tenk.fyi

Intellia Therapeutics, Inc.

NTLANasdaq· In Vitro & In Vivo Diagnostic Substances

Price History

Revenue

$67.7M

16.9% YoY

Net Income

-$412.7M

20.5% YoY

EPS

$-3.81

27.4% YoY

Cash

$155.5M

17.8% YoY

FY 2025 · As of 2025-12-31